---
title: "New MDCG Guidance on Clinical Evidence for Orphan IVDs"
description: "MDCG 2026-6 explains how the IVDR clinical evidence requirements can be applied in a balanced and proportionate way to IVDs intended for very small patient populations."
url: https://qbdgroup.com/en/regulatory-updates/mdcg-2026-6-clinical-evidence-orphan-ivds
type: "Regulatory update"
language: en
published: 2026-11-17
author: "Kirsten Van Garsse"
category: "Regulatory Update"
publisher: "QbD Group"
citation: "QbD Group, \"New MDCG Guidance on Clinical Evidence for Orphan IVDs\", https://qbdgroup.com/en/regulatory-updates/mdcg-2026-6-clinical-evidence-orphan-ivds"
---
# New MDCG Guidance on Clinical Evidence for Orphan IVDs
> MDCG 2026-6 explains how the IVDR clinical evidence requirements can be applied in a balanced and proportionate way to IVDs intended for very small patient populations.

On 03 November 2026, the Medical Device Coordination Group (MDCG) published [**MDCG 2026-6: Clinical evidence for orphan in vitro diagnostic medical devices**](https://health.ec.europa.eu/latest-updates/new-guidance-document-mdcg-2026-6-guidance-clinical-evidence-orphan-ivds-2026-11-03_en), providing guidance on how the IVDR clinical evidence requirements can be applied in a balanced and proportionate way to IVDs intended for very small patient populations.

**The guidance introduces criteria for orphan IVD status and explains when limitations in pre-market clinical performance data may be acceptable.** It is relevant to IVDs across all risk classes and addresses manufacturers, notified bodies, expert panels, health institutions and regulators.

## Key Points

- **Orphan IVD criteria:**
  - An IVD qualifies if it is specifically intended to test persons for a disease, condition or circumstance present in not more than 12,000 individuals in the EU per year, AND there are insufficient available alternatives or the IVD is expected to provide a clinical benefit compared to alternatives or the state of the art
  - The criterion is based on the incidence of the disease, condition or circumstance, not on the number of tests performed per year
  - Orphan status does not confer market exclusivity
- **Orphan indications and subpopulations:**
  - Where an IVD has both orphan and non-orphan indications, the principles may be applied to the orphan indication only, if duly justified
  - Arbitrarily limiting the intended use to a subpopulation to meet the incidence criterion is not considered sufficient
- **Justification of orphan status:**
  - The manufacturer must substantiate the claim, addressing at least epidemiological and IVD-related considerations
  - This justification is distinct from the clinical evidence required for conformity assessment
- **Acceptability of limited pre-market clinical performance data:**
  - Limitations may be acceptable if justified, but sufficient clinical evidence must still demonstrate the expected clinical benefit and that the device performs as intended with an acceptable level of safety
  - Remaining limitations are to be addressed through PMS and PMPF, and users must be informed of the orphan status and the limitations
- **Non-clinical data and extrapolation:**
  - The guidance describes the role of non-clinical data in supporting orphan IVDs
  - Annex 3 addresses the extrapolation of clinical performance data from non-orphan populations to orphan indications
- **PMPF expectations:**
  - A structured and detailed PMPF plan, subject to notified body review, is expected for orphan IVDs with accepted limitations
- **Notified body activities:**
  - Orphan status should be checked as early as possible, e.g. during the application phase
  - Certificates with specific conditions or provisions may be used, and compliance is monitored through surveillance
  - Unfulfilled conditions could ultimately lead to suspension or withdrawal of the certificate
- **Expert panel advice:**
  - Consultation is optional and independent of the performance evaluation consultation procedure (PECP)
  - Advice may cover orphan status and/or the data needed for the clinical performance evaluation, with indicative timelines of 60 days (orphan status only) and 90 days (status and data, simple advice)
  - Manufacturers may seek early advice; late-stage advice is requested by the notified body or, in exceptional cases during the IVDR transitional periods, by the manufacturer
- **Health institutions:**
  - The general principles in Part A (sections 4 to 9, and Annexes 3 and 4) are relevant to in-house orphan IVDs under Article 5(5) IVDR
  - The procedural part (Part B) does not apply to health institutions
- **Status of the document:**
  - MDCG 2026-6 is guidance endorsed by the MDCG; it is not a European Commission document and is not legally binding
  - Annexes provide examples of orphan IVDs, orphan-specific factors for the performance evaluation report, extrapolation considerations and considerations for clinical performance studies

MDCG 2026-6 provides a common reference for how clinical evidence can be approached for IVDs addressing very small patient populations, with a strong emphasis on the justification of orphan status and on post-market follow-up. The guidance is not legally binding and should be read together with the IVDR and other MDCG guidance, in particular MDCG 2022-2.

## What does this mean for you?

Manufacturers of IVDs intended for rare diseases, conditions or circumstances should consider whether their devices may fall within the orphan IVD criteria, and how this affects their performance evaluation and PMS/PMPF planning.

The guidance encourages early alignment with the notified body and, where relevant, with the expert panels. Health institutions manufacturing in-house orphan IVDs should also review the relevant principles.

<!-- no_internal_links -->
---
Source: https://qbdgroup.com/en/regulatory-updates/mdcg-2026-6-clinical-evidence-orphan-ivds — © QbD Group. Quote freely with attribution and a link back.